Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer

PURPOSE: Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density (BMD) and increase fracture risk in men with prostate cancer. Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known. PATIENTS AND METHODS: In a 12-month stud...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Michaelson, M. Dror, Kaufman, Donald S., Lee, Hang, McGovern, Francis J., Kantoff, Philip W., Fallon, Mary Anne, Finkelstein, Joel S., Smith, Matthew R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2007
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3047397/
https://ncbi.nlm.nih.gov/pubmed/17369566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2006.07.3361
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller